Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) has announced significant progress in its proprietary Mueller iodine extraction process, which is designed to recover high-purity iodine from oilfield brine. The company's latest laboratory results show iodine production at 99.8% purity with overall recovery exceeding 90%, marking a key step toward establishing a domestic iodine supply for the North American radiology contrast media market.
The Mueller process is being developed to address the growing need for iodine, a critical raw material used in iodinated contrast agents for medical imaging. Currently, North America relies heavily on imported iodine, creating supply chain vulnerabilities. Voyageur's approach aims to extract iodine from produced brine, a waste product of oil and gas operations, thereby offering a new revenue stream for producers and improving supply chain security.
According to the company, laboratory operations in Houston, Texas have successfully demonstrated the process using real Anadarko and Permian Basin produced water. The process also generates clean brine suitable for disposal or reinjection, aligning with zero-liquid-discharge objectives. A mobile field-capable pilot unit, sized to treat 80,000 liters per day, has been constructed and is scheduled for field testing in the coming weeks, with operations planned for September 2026.
“Achieving 99.8% purity and greater than 90% recovery in laboratory testing using real oilfield brine provides meaningful technical validation as we prepare for field pilot operations,” said Brent Willis, President and CEO of Voyageur. “This work supports our broader strategy of building a secure, vertically integrated supply chain for radiology drugs.”
The field pilot will provide operating data under real-world conditions, which is critical for validating the technology's commercial viability. The company has also completed a preliminary design basis for a 200 metric ton per year plant and conducted techno-economic assessments indicating a low operating cost and environmental profile.
Voyageur's modular production concept involves deploying 200-tonne-per-year units at multiple saltwater disposal sites, where iodine concentrate can be produced and then transported to a central hub for final polishing, prilling, and packaging. This approach is designed to be scalable and adaptable to various brine sources.
The strategic importance of this development extends beyond Voyageur. For oil and gas operators and midstream water companies, produced brine is often viewed as a disposal burden. Voyageur's process could transform it into a valuable resource, potentially offsetting disposal costs and generating new revenue. For the medical imaging industry, a domestic source of high-purity iodine could reduce dependency on imports, which are subject to geopolitical and market fluctuations.
Voyageur's long-term goal is to develop iodine production capacity of up to 1,000 tonnes per year to support its future iodine-based contrast pharmaceutical production. This is part of its broader vertically integrated strategy, which also includes the Frances Creek barium project. By controlling raw material sourcing, the company aims to lower costs and ensure quality, positioning itself as a key player in the contrast media market.
The company plans to provide further updates as field testing begins and more data is collected. The success of the field pilot will be a crucial milestone in advancing the Mueller process toward commercial deployment, potentially reshaping the iodine supply landscape in North America.
